EP Patent

EP4285902B1 — Augmented acid alpha-glucosidase for the treatment of pompe disease

Assigned to Amicus Therapeutics Inc · Expires 2025-11-19 · 0y expired

What this patent protects

Patent listed against Zavesca.

Drugs covered by this patent

Zavesca (MIGLUSTAT) · AstraZeneca

Patent Metadata

Patent number: EP4285902B1
Jurisdiction: EP
Classification: —
Expires: 2025-11-19
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.